Seer Reports First Quarter 2024 Financial Results
08 mai 2024 16h05 HE
|
Seer, Inc.
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial...
Seer Launches New Technology Access Center in Europe to Expand Accessibility to Unbiased Proteomic Solutions
08 mai 2024 16h03 HE
|
Seer, Inc.
New Seer Technology Access Center to open in Bonn, Germany Provides life sciences researchers conducting proteomic studies full-service access to the Seer Proteograph™ Product Suite and mass...
Seer to Report First Quarter 2024 Financial Results on May 8, 2024
23 avr. 2024 16h05 HE
|
Seer, Inc.
REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it...
Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook
29 févr. 2024 16h05 HE
|
Seer, Inc.
REDWOOD CITY, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial...
Seer to Participate in the TD Cowen 44th Annual Health Care Conference
21 févr. 2024 16h05 HE
|
Seer, Inc.
REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the...
Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker Discovery
06 févr. 2024 08h00 HE
|
Seer, Inc.
Study led by Weill Cornell Medicine demonstrates identification of protein altering variants for population-scale protein quantitative trait loci (pQTL) studies Proteograph Product Suite enables...
Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
01 févr. 2024 16h05 HE
|
Seer, Inc.
REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it...
Seer to Present at the J.P. Morgan 42nd Annual Health Care Conference
21 déc. 2023 16h05 HE
|
Seer, Inc.
REDWOOD CITY, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the...
Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum
10 nov. 2023 09h00 HE
|
Seer, Inc.
REDWOOD CITY, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced company...
Seer Wins Proteomics Solution of the Year by BioTech Breakthrough and Named #5 on Deloitte Technology Fast 500
08 nov. 2023 09h00 HE
|
Seer, Inc.
REDWOOD CITY, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the...